Results 31 to 40 of about 62,675 (241)

Partial Reconstitution of Photoreceptor cGMP Phosphodiesterase Characteristics in cGMP Phosphodiesterase-5 [PDF]

Journal of Biological Chemistry, 2001
Photoreceptor cGMP phosphodiesterases (PDE6) are uniquely qualified to serve as effector enzymes in the vertebrate visual transduction cascade. In the dark-adapted photoreceptors, the activity of PDE6 is blocked via tight association with the inhibitory gamma-subunits (Pgamma).
A E, Granovsky, N O, Artemyev
openaire   +2 more sources

Continuous use of glycomacropeptide in the nutritional management of patients with phenylketonuria: a clinical perspective

Orphanet Journal of Rare Diseases, 2021
Background In phenylketonuria (PKU), modified casein glycomacropeptide supplements (CGMP-AA) are used as an alternative to the traditional phenylalanine (Phe)-free L-amino acid supplements (L-AA).
Maria João Pena, Alex Pinto, Manuela Ferreira de Almeida, Catarina de Sousa Barbosa, Paula Cristina Ramos, Sara Rocha, Arlindo Guimas, Rosa Ribeiro, Esmeralda Martins, Anabela Bandeira, Cláudia Camila Dias, Anita MacDonald, Nuno Borges, Júlio César Rocha   +13 more
doaj   +1 more source

cGMP-dependent protein kinase protects cGMP from hydrolysis by phosphodiesterase-5 [PDF]

Biochemical Journal, 2003
The physiological effects of cGMP are largely determined by the activities of intracellular receptors, including cGMP-dependent protein kinase (PKG) and cGMP-binding cyclic nucleotide phosphodiesterases (PDEs), and the distribution of cGMP among these receptors dictates activity of the signalling pathway.
Jun, Kotera, Kennard A, Grimes, Jackie D, Corbin, Sharron H, Francis   +3 more
openaire   +2 more sources

Electrosynthesis of Bioactive Chemicals, From Ions to Pharmaceuticals

Advanced Functional Materials, EarlyView.
This review discusses recent advances in electrosynthesis for biomedical and pharmaceutical applications. It covers key electrochemical materials enabling precise delivery of ions and small molecules for cellular modulation and disease treatment, alongside catalytic systems for pharmaceutical synthesis.
Gwangbin Lee, Sojin Kim, Myeongeun Lee, Kyoungsuk Jin, Jimin Park   +4 more
wiley   +1 more source

Intracellular cGMP increase is not involved in thyroid cancer cell death

PLoS ONE, 2023
Introduction Type 5 phosphodiesterase (PDE5) inhibitors (PDE5i) lead to intracellular cyclic-guanosine monophosphate (cGMP) increase and are used for clinical treatment of erectile dysfunction.
Sara D’ Alessandro, Elia Paradiso, Clara Lazzaretti, Samantha Sperduti, Carmela Perri, Francesco Antoniani, Sara Righi, Manuela Simoni, Giulia Brigante, Livio Casarini   +9 more
doaj   +2 more sources

Sildenafil Potentiates a cGMP-Dependent Pathway to Promote Melanoma Growth

Cell Reports, 2016
Sildenafil, an inhibitor of the cGMP-degrading phosphodiesterase 5 that is used to treat erectile dysfunction, has been linked to an increased risk of melanoma. Here, we have examined the potential connection between cGMP-dependent signaling cascades and
Sandeep Dhayade, Susanne Kaesler, Tobias Sinnberg, Hyazinth Dobrowinski, Stefanie Peters, Ulrike Naumann, He Liu, Robert E. Hunger, Martin Thunemann, Tilo Biedermann, Birgit Schittek, Hans-Uwe Simon, Susanne Feil, Robert Feil   +13 more
doaj   +1 more source

Cyclic GMP and PKG Signaling in Heart Failure

Frontiers in Pharmacology, 2022
Cyclic guanosine monophosphate (cGMP), produced by guanylate cyclase (GC), activates protein kinase G (PKG) and regulates cardiac remodeling. cGMP/PKG signal is activated by two intrinsic pathways: nitric oxide (NO)-soluble GC and natriuretic peptide (NP)
Genri Numata, Genri Numata, Eiki Takimoto, Eiki Takimoto   +3 more
doaj   +1 more source

Sculpting the Future of Bone: The Evolution of Absorbable Materials in Orthopedics

Advanced Materials, EarlyView.
This review summarizes the current status of polymeric, ceramic, and metallic absorbable materials in orthopedic applications, and highlights several innovative strategies designed to enhance mechanical performance, control degradation, and promote bioactivity. We also discuss the progress and translational potential of absorbable materials in treating
Zhao Wang, Zehui Lv, Xuejie Cai, Yingjie Wang, Bo Peng, Haojing Xu, Hualuo Pang, Xingdong Yang, Jiawei Xu, Yixin Bian, Bin Feng, Peng Wen, Yufeng Zheng, Xisheng Weng   +13 more
wiley   +1 more source

Targeting Adipose Tissue Function Protects Against Heart Failure with Preserved Ejection Fraction

Advanced Science, EarlyView.
This study explores the role adipose tissue (AT) phenotypes have in determining cardiovascular outcomes in an obesity‐related heart failure with preserved ejection fraction (HFpEF) model. Pharmacological induction of thermogenesis promoted resilience to HFpEF‐induced remodeling of AT and conferred cardioprotection. Surgical and genetic models confirmed
Jordan Jousma, Zhenbo Han, Jooman Park, Gege Yan, Sen Zhang, Youjeong Kwon, Sarath Babu Nukala, Jindpreet Kandola, Sandra Pinho, Chong Wee Liew, Yuwei Jiang, Sang‐Ging Ong   +11 more
wiley   +1 more source

Rise of cGMP by partial phosphodiesterase-3A degradation enhances cardioprotection during hypoxia

Redox Biology, 2021
3′,5′-cyclic guanosine monophosphate (cGMP) is a druggable second messenger regulating cell growth and survival in a plethora of cells and disease states, many of which are associated with hypoxia. For example, in myocardial infarction and heart failure (
Nadja I. Bork, Anna Kuret, Melanie Cruz Santos, Cristina E. Molina, Beate Reiter, Hermann Reichenspurner, Andreas Friebe, Boris V. Skryabin, Timofey S. Rozhdestvensky, Michaela Kuhn, Robert Lukowski, Viacheslav O. Nikolaev   +11 more
doaj   +1 more source